Skip to main content
SpringerLink
Log in

Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis

  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

The expression levels of histone deacetylase 2 (HDAC2), eukaryotic initiation factor 5 (eIF5), and eukaryotic initiation factor 6 (eIF6), and relationship between HDAC2 and eIF5 or eIF6 in lung cancer tissues were investigated, in order to charify the relationship between HDAC2 and the prognosis of lung cancer patients and its influence on the expression of eIF5 and eIF6.

Methods

The expression of HDAC2, eIF5, and eIF6 in lung cancer tissues was detected by quantitative reverse transcription polymerase chain reaction. The expression correlation between HDAC2 and eIF5 or eIF6 was tested using a t test. The correlation between HDAC2 and eIF5 or eIF6 was analyzed using the TCGA database. The identified cells were constructed with small interfering siRNA and HDAC2 overexpression plasmid. The proliferation and migration ability of the identified cells was investigated by CCK8 and Transwell assays, respectively.

Results

HDAC2, eIF5, and eIF6 were overexpressed in lung cancer tissues, and HDAC2 expression level was negatively correlated with the prognosis of lung cancer patients. HDAC2 expression level was positively correlated with eIF5 and eIF6 expression levels. HDAC2 could regulate the expression of eIF5 and eIF6. The regulation of proliferation and invasion of lung cancer cells by HDAC2 depended on eIF5 and eIF6.

Conclusion

HDAC2, eIF5, and eIF6 were closely related with lung cancer tumorigenesis, which might be potential biological markers and therapeutic targets for lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015,65(2):87–108

    Article  Google Scholar 

  2. Chheang S, Brown K. Lung cancer staging: clinical and radiologic perspectives. Semin Intervent Radiol, 2013, 30(2):99–113

    Article  Google Scholar 

  3. Cancer Genome Atlas Research N. Author Correction: Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2018,559(7715):E12

    Article  Google Scholar 

  4. Lee YM, Kim SJ, Lee JH, et al. Inhaled corticosteroids in COPD and the risk of lung cancer. Int J Cancer, 2018, 143(9):2311–2318

    Article  CAS  Google Scholar 

  5. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2008,70(3):685–692

    Article  Google Scholar 

  6. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol, 2008,9(3):206–218

    Article  CAS  Google Scholar 

  7. Kelly RD, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans, 2013, 41(3):741–749

    Article  CAS  Google Scholar 

  8. Li L, Mei DT, Zeng Y. HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin. Biomed Pharmacother, 2016,84:284–290

    Article  CAS  Google Scholar 

  9. Conte MR, Kelly G, Babon J, et al. Structure of the eukaryotic initiation factor (eIF) 5 reveals a fold common to several translation factors. Biochemistry, 2006,45(14):4550–4558

    Article  CAS  Google Scholar 

  10. Lopez Ribera I, Ruiz-Avila L, Puigdomenech P. The eukaryotic translation initiation factor 5, eIF-5, a protein from Zea mays, containing a zinc-finger structure, binds nucleic acids in a zinc-dependent manner. Biochem Biophys Res Commun, 1997,236(2):510–516

    Article  CAS  Google Scholar 

  11. Lin J, Yu X, Xie L, et al. eIF6 Promotes Colorectal Cancer Proliferation and Invasion by Regulating AKT-Related Signaling Pathways. J Biomed Nanotechnol, 2019,15(7):1556–1567

    Article  CAS  Google Scholar 

  12. Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer, 2008,8:381

    Article  Google Scholar 

  13. Noh JH, Bae HJ, Eun JW, et al. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res, 2014,74(6):1728–1738

    Article  CAS  Google Scholar 

  14. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ, 2005,12(4):395–404

    Article  CAS  Google Scholar 

  15. Gemoll T, Roblick UJ, Szymczak S, et al. HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers. Cell Mol Life Sci, 2011,68(19):3261–3274

    Article  CAS  Google Scholar 

  16. Caraglia M, Park MH, Wolff EC, et al. eIF5A isoforms and cancer: two brothers for two functions? Amino Acids, 2013,44(1):103–109

    Article  CAS  Google Scholar 

  17. Mathews MB, Hershey JW. The translation factor eIF5A and human cancer. Biochim Biophys Acta, 2015,1849(7):836–844

    Article  CAS  Google Scholar 

  18. Ruggero D. Translational control in cancer etiology. Cold Spring Harb Perspect Biol, 2013,5(2):a12336

    Article  Google Scholar 

  19. Sanvito F, Vivoli F, Gambini S, et al. Expression of a highly conserved protein, p27BBP, during the progression of human colorectal cancer. Cancer Res, 2000,60(3):510–516

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China

    Shao-xin Cai, Wen-shu Chen, Wei Zeng, Xue-fei Cheng, Meng-bo Lin & Jin-si Wang

  2. Department of Surgical Oncology, Fujian Provincial Hospital, Fuzhou, 350001, China

    Shao-xin Cai, Wei Zeng, Xue-fei Cheng, Meng-bo Lin & Jin-si Wang

  3. Department of Thoracic Surgery, Fujian Provincial Hospital, Fuzhou, 350001, China

    Wen-shu Chen

Authors
  1. Shao-xin Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen-shu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xue-fei Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meng-bo Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jin-si Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin-si Wang.

Ethics declarations

The authors have no conflict of interest.

Additional information

The study was supported by the Startup Fund for scientific research, Fujian Medical University (No. 2018QH1114), and Fujian Health and Healthy Middle-aged and Young Backbone Talents Training Project (No. 2019-ZQN-4).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cai, Sx., Chen, Ws., Zeng, W. et al. Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis. CURR MED SCI 41, 764–769 (2021). https://doi.org/10.1007/s11596-021-2389-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-021-2389-z

Key words

Search

Navigation